These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 21123835)
1. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835 [TBL] [Abstract][Full Text] [Related]
2. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Nan H; Qureshi AA; Hunter DJ; Han J Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047 [TBL] [Abstract][Full Text] [Related]
3. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study. Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146 [TBL] [Abstract][Full Text] [Related]
4. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782 [TBL] [Abstract][Full Text] [Related]
5. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029 [TBL] [Abstract][Full Text] [Related]
6. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942 [TBL] [Abstract][Full Text] [Related]
7. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639 [TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124 [TBL] [Abstract][Full Text] [Related]
9. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578 [TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156 [TBL] [Abstract][Full Text] [Related]
11. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. Jiang DK; Wang WZ; Ren WH; Yao L; Peng B; Yu L J Invest Dermatol; 2011 Jan; 131(1):220-8. PubMed ID: 20861852 [TBL] [Abstract][Full Text] [Related]
12. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Chien WP; Wong RH; Cheng YW; Chen CY; Lee H Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079 [TBL] [Abstract][Full Text] [Related]
13. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions. Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Deka S; Ghosh SK; Choudhury Y Asian Pac J Cancer Prev; 2015; 16(14):5767-72. PubMed ID: 26320449 [TBL] [Abstract][Full Text] [Related]
14. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Nan H; Qureshi AA; Hunter DJ; Han J Br J Dermatol; 2008 Aug; 159(2):314-21. PubMed ID: 18510673 [TBL] [Abstract][Full Text] [Related]
15. Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. Machado-Neto JA; Traina F; De Melo Campos P; Andreoli-Risso MF; Costa FF; Olalla Saad ST Neoplasma; 2012; 59(5):530-5. PubMed ID: 22668018 [TBL] [Abstract][Full Text] [Related]
16. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Xu B; Xu Z; Cheng G; Min ZC; Mi Y; Zhang ZZ; Tao J; Li PC; Wang ML; Tang JL; Zhang ZD; Zhang W; Wu HF; Feng NH; Hua LX Cancer Genet Cytogenet; 2010 Oct; 202(2):76-81. PubMed ID: 20875869 [TBL] [Abstract][Full Text] [Related]
17. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore. Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626 [TBL] [Abstract][Full Text] [Related]
18. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females. Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330 [TBL] [Abstract][Full Text] [Related]
19. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596 [TBL] [Abstract][Full Text] [Related]
20. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population. Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]